Rosario P.W.,Santa Casa de Belo Horizonte Belo Horizonte |
Mourao G.F.,Santa Casa de Belo Horizonte Belo Horizonte |
Calsolari M.R.,Santa Casa de Belo Horizonte Belo Horizonte
Clinical Endocrinology | Year: 2016
Objective: This study evaluated low-activity 131I therapy in patients with papillary thyroid carcinoma (PTC) of intermediate risk 'with higher risk features' who had low nonstimulated thyroglobulin (Tg) after thyroidectomy. Design and Patients: This was a prospective study including 102 patients with tumours >1 cm and aggressive histology; and/or >3 positive lymph node (LN) or LN >1·5 cm or exhibiting macroscopic extracapsular extension, and clinically apparent (cN1); and/or a combination of a tumour >4 cm, microscopic extrathyroidal extension and LN metastases (cN1). After thyroidectomy, all patients had nonstimulated Tg < 0·3 ng/ml and negative antithyroglobulin antibodies (TgAb) and neck ultrasonography (US). The patients were treated with a low activity of 131I (1110 or 1850 MBq). Results: Post-therapy whole-body scanning (RxWBS) showed ectopic uptake in four patients. When evaluated 12 months after 131I therapy, nonstimulated Tg ≤ 0·2 ng/ml with negative TgAb and US, defined as excellent response to initial therapy, was achieved in 101 patients (99%). Only one patient with positive initial RxWBS had structural disease. During follow-up, four patients (4%) relapsed, including LN metastases in two, pulmonary metastases in one, and elevated Tg in one. The other 98 patients remained with nonstimulated Tg ≤ 0·2 ng/ml and negative TgAb and US. There was no case of death due to the tumour. Conclusions: We conclude that in intermediate-risk patients 'with higher risk features', low nonstimulated Tg measured with a second-generation assay can be used as criterion for the administration of low 131I activities (1850 MBq or less). © 2016 John Wiley & Sons Ltd.